Stock Ratings / Health Care / CAPR / options

RZLT (33) AVTX (34) EBS (53) RLMD (44) ⌘ Pro Terminal →

Capricor Therapeutics Inc. (CAPR) Options Positioning, Max Pain & Unusual Sweeps

$6.63 +6.42% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.69

Capricor Therapeutics Inc. (CAPR) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $385.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.69 (+0.97%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-4.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CAPR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (49/100 Composite)

🔍 WHY CAPR SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (29% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (24% of score)

Altman Z-Score 3.38 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$7.83-14.3% Next Q

Q2 (-2Q)

Grade C-$6.71-11.6% Next Q

Q3 (-1Q)

Grade C-$5.93+11.8% Next Q

Current

Grade D$6.63-5.4% Hist 90D α

Trajectory: C (57) → D (49)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CAPR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CAPR currently carries a cautious 49/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.06) and Max Pain ($6.96) forces dealer call-delta covering toward $42.39.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CAPR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CAPR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 49%NO 51%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CAPR)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CAPR.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CAPR)

✓Walkthrough of CAPR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CAPR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -80.26%▲ RESISTANCE BREAKOUT

2026-10-30O $6.58H $6.64L $6.14C $6.63VOL 3.31M

RES: $4.08SUP: $5.80SMA50: $8.06SMA200: $20.67

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CAPR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CAPR Butterfly Map → + Track CAPR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CAPR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CAPR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CAPR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CAPR)

Health Care Rank #360 of 1016 ⚔️ RZLT vs CAPR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CAPR vs. RZLT, AVTX, EBS, RLMD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Capricor Therapeutics Inc. (CAPR) ranks #360 by composite RQD confidence (49/100, grade D) and #485 by equity capitalization ($385.5M). Within this direct 5-issuer industry benchmark cohort, EBS leads on earnings valuation at 7.0x trailing P/E, while EBS leads on capital efficiency and profitability with 8.9% ROIC and 56.1% gross margin. EBS currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with CAPR at 49/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CAPR ACTIVE Capricor Therapeutics Inc.	D	49/100	—	—	-35.0%	+6.42%	$385.5M	Benchmark Subject
RZLT Rezolute Inc. (NV)	E	33/100	—	—	-35.0%	-2.37%	$398.5M	/rzlt-vs-capr →
AVTX Avalo Therapeutics Inc.	E	34/100	—	—	-35.0%	+4.49%	$399.0M	/avtx-vs-capr →
EBS Emergent BioSolutions Inc.	D+	53/100	7.0x	56.1%	8.9%	+1.83%	$370.2M	/ebs-vs-capr →
RLMD Relmada Therapeutics Inc.	D	44/100	—	—	-35.0%	+2.69%	$366.9M	/rlmd-vs-capr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001133869

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Capricor Therapeutics Inc. (CAPR) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $22.3M , and -100.0% cumulative change since FY2023) , GAAP net income of -$105.0M, operating cash flow of -$69.8M, and free cash flow of -$72.7M (-76.7% YoY). On the balance sheet, CAPR closed FY2025 with $355.9M in total assets against $0 in total debt (Altman Z-Score: 3.38, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$105.0M	-$69.8M	-$72.7M	$355.9M	—
FY2024 (FY)	2024-12-31	$22.3M	-$40.5M	-$40.0M	-$41.2M	$170.5M	—
FY2023 (FY)	2023-12-31	$25.2M	-$22.3M	-$25.6M	-$25.6M	—	—

3. CAPR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CAPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Capricor Therapeutics Inc. (NASDAQ: CAPR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $6.63 (+6.42% 1D, market cap $385.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CAPR ranks #360 in composite RQD confidence.

How does CAPR compare to RZLT and AVTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CAPR carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RZLT (Rezolute Inc. (NV)) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $398.5M) and AVTX (Avalo Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $399.0M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CAPR?

Per CAPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001133869), Capricor Therapeutics Inc. generated $0 in revenue (-100.0% YoY), -$105.0M in net income, and -$72.7M in free cash flow against $355.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CAPR trading relative to its 50-day, 200-day, and 52-week technical levels?

CAPR last traded at $6.63 (+6.42% on volume of 3,330,969 shares), positioning the stock -17.74% below its 50-day simple moving average ($8.06) and -67.92% below its 200-day simple moving average ($20.67). Across its 52-week range of $2.96 to $40.37, CAPR sits at the 9.8% percentile with a 14-day RSI of 41.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.80 to $7.46).